These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 28237784)
21. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management? Xian Z; Quinones AK; Tozbikian G; Zynger DL Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y J BUON; 2013; 18(1):57-63. PubMed ID: 23613389 [TBL] [Abstract][Full Text] [Related]
23. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy. Tan S; Fu X; Xu S; Qiu P; Lv Z; Xu Y; Zhang Q Pathol Oncol Res; 2021; 27():1609972. PubMed ID: 34987312 [No Abstract] [Full Text] [Related]
24. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer. Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368 [TBL] [Abstract][Full Text] [Related]
25. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Matsubara N; Mukai H; Masumoto M; Sasaki M; Naito Y; Fujii S; Wada N Breast Cancer Res Treat; 2014 Aug; 147(1):95-102. PubMed ID: 25106660 [TBL] [Abstract][Full Text] [Related]
26. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients. Wang M; Wei Z; Kong J; Zhao H Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525 [TBL] [Abstract][Full Text] [Related]
27. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. Romero Q; Bendahl PO; Klintman M; Loman N; Ingvar C; Rydén L; Rose C; Grabau D; Borgquist S BMC Cancer; 2011 Aug; 11():341. PubMed ID: 21819622 [TBL] [Abstract][Full Text] [Related]
28. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454 [TBL] [Abstract][Full Text] [Related]
29. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974 [TBL] [Abstract][Full Text] [Related]
30. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556 [TBL] [Abstract][Full Text] [Related]
31. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy. Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798 [TBL] [Abstract][Full Text] [Related]
32. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851 [TBL] [Abstract][Full Text] [Related]
33. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Assersohn L; Salter J; Powles TJ; A'hern R; Makris A; Gregory RK; Chang J; Dowsett M Breast Cancer Res Treat; 2003 Nov; 82(2):113-23. PubMed ID: 14692655 [TBL] [Abstract][Full Text] [Related]
34. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Guestini F; Ono K; Miyashita M; Ishida T; Ohuchi N; Nakagawa S; Hirakawa H; Tamaki K; Ohi Y; Rai Y; Sagara Y; Sasano H; McNamara KM Breast Cancer Res Treat; 2019 Jan; 173(2):275-288. PubMed ID: 30306430 [TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M Breast Cancer Res Treat; 2009 Jul; 116(1):53-68. PubMed ID: 18592370 [TBL] [Abstract][Full Text] [Related]
36. [Association between hormone receptors and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients]. Wei Y; Li JF; Wang TF; Xie YT; Fan ZQ; Fan T; Lu AP; Ouyang T; Lin BY Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Oct; 39(5):481-3. PubMed ID: 17940564 [TBL] [Abstract][Full Text] [Related]
37. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. Robertson S; Stålhammar G; Darai-Ramqvist E; Rantalainen M; Tobin NP; Bergh J; Hartman J J Clin Pathol; 2018 Sep; 71(9):787-794. PubMed ID: 29588372 [TBL] [Abstract][Full Text] [Related]
38. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel. Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441 [TBL] [Abstract][Full Text] [Related]
39. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606 [TBL] [Abstract][Full Text] [Related]
40. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]